PMID- 37252215
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230531
IS  - 1735-5370 (Print)
IS  - 2008-2371 (Electronic)
IS  - 1735-5370 (Linking)
VI  - 18
IP  - 1
DP  - 2023 Jan
TI  - The Long-Term Response to Treatment with Calcium Channel Blockers in Patients 
      with Idiopathic Pulmonary Arterial Hypertension.
PG  - 62-67
LID - 10.18502/jthc.v18i1.12583 [doi]
AB  - BACKGROUND: Long-term outcomes in patients with idiopathic pulmonary arterial 
      hypertension (IPAH) treated with calcium channel blockers (CCBs) are not well 
      documented. Therefore, this study aimed to determine the long-term response to 
      treatment with CCBs in patients with IPAH. METHODS: This retrospective cohort 
      study was performed on 81 patients with IPAH admitted to our center. 
      Vasoreactivity testing with adenosine was performed in all patients. Twenty-five 
      patients showed a positive response to vasoreactivity testing and were included 
      in the analysis. RESULTS: Of 24 patients, 20 (83.3%) were female, and the mean 
      age of the patients was 45.90+/-10.42 years. Fifteen patients improved after 1 year 
      on CCB therapy (the long-term CCB responders group), and 9 showed no improvement 
      (the CCB failure group). The CCB responders group had a greater proportion of 
      patients in New York Heart Association (NYHA) functional class I or II (93.3%), a 
      longer distance walked, and less severe hemodynamic parameters. At the 1-year 
      evaluation, the long-term CCB responders had more improvements in the mean 
      6-minute walk test result (437.43+/-125.32 vs 268.17+/-130.06; P=0.040), the mixed 
      venous oxygen saturation level (71.84+/-9.87 vs 59.03+/-9.95; P=0.041), and the 
      cardiac index (4.76+/-1.12 vs 3.15+/-0.90; P=0.012). Additionally, mPAP was lower in 
      the long-term CCB responders group (47.35+/-12.70 vs 67.23+/-14.08; P=0.034). 
      Finally, all the CCB responders were in NYHA functional class I or II (P=0.001). 
      CONCLUSION: Our study illustrated that long-term treatment with oral CCBs was 
      effective in 60% of acute responders and 18.5% of the entire study population.
CI  - Copyright (c) 2023 Tehran University of Medical Sciences. Published by Tehran 
      University of Medical Sciences.
FAU - Kiani, Azam
AU  - Kiani A
AD  - Rajaie Cardiovascular Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Omidvar, Razieh
AU  - Omidvar R
AD  - Rajaie Cardiovascular Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Naderi, Nasim
AU  - Naderi N
AD  - Rajaie Cardiovascular Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Taghavi, Sepideh
AU  - Taghavi S
AD  - Rajaie Cardiovascular Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Mirtajaddini, Marzieh
AU  - Mirtajaddini M
AD  - Rajaie Cardiovascular Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - J Tehran Heart Cent
JT  - The journal of Tehran Heart Center
JID - 101289255
PMC - PMC10225025
OTO - NOTNLM
OT  - Calcium channel blockers
OT  - Hemodynamic monitoring
OT  - Iran
OT  - Pulmonary hypertension
EDAT- 2023/05/30 13:07
MHDA- 2023/05/30 13:08
PMCR- 2023/01/01
CRDT- 2023/05/30 11:51
PHST- 2022/10/13 00:00 [received]
PHST- 2022/12/15 00:00 [accepted]
PHST- 2023/05/30 13:08 [medline]
PHST- 2023/05/30 13:07 [pubmed]
PHST- 2023/05/30 11:51 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - JTHC-18-62 [pii]
AID - 10.18502/jthc.v18i1.12583 [doi]
PST - ppublish
SO  - J Tehran Heart Cent. 2023 Jan;18(1):62-67. doi: 10.18502/jthc.v18i1.12583.